Literature DB >> 33149761

Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention.

Charlotte Skinner1, Alex J Thompson2, Mark R Thursz1, Julian R Marchesi1, Nikhil Vergis3.   

Abstract

Increased bacterial translocation (BT) across the gut barrier due to greater intestinal permeability (IP) is seen across a range of conditions, including alcohol-related liver disease (ArLD). The phenomenon of BT may contribute to both the pathogenesis and the development of complications in ArLD. There are a number of methods available to assess IP and in this review we look at their various advantages and limitations. The knowledge around BT and IP in ArLD is also reviewed, as well as the therapeutic strategies currently in use and in development.
© The Author(s), 2020.

Entities:  

Keywords:  alcohol-related liver disease; bacterial translocation; cirrhosis; gut barrier; intestinal permeability

Year:  2020        PMID: 33149761      PMCID: PMC7580143          DOI: 10.1177/1756284820942616

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  125 in total

1.  Serum zonulin in patients with inflammatory bowel disease: a pilot study.

Authors:  Gian Paolo Caviglia; Francesca Dughera; Davide G Ribaldone; Chiara Rosso; Maria L Abate; Rinaldo Pellicano; Francesca Bresso; Antonina Smedile; Giorgio M Saracco; Marco Astegiano
Journal:  Minerva Med       Date:  2018-08-28       Impact factor: 4.806

2.  Abnormalities in proximal small bowel motility in patients with cirrhosis.

Authors:  J Chesta; C Defilippi; C Defilippi
Journal:  Hepatology       Date:  1993-05       Impact factor: 17.425

3.  Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.

Authors:  Jasmohan S Bajaj; Genta Kakiyama; Tor Savidge; Hajime Takei; Zain A Kassam; Andrew Fagan; Edith A Gavis; William M Pandak; Hiroshi Nittono; Phillip B Hylemon; Prapaporn Boonma; Anthony Haag; Douglas M Heuman; Michael Fuchs; Binu John; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Hepatology       Date:  2018-09-20       Impact factor: 17.425

4.  Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Hepatol Int       Date:  2018-10-04       Impact factor: 6.047

5.  Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice.

Authors:  Phillipp Hartmann; Peng Chen; Hui J Wang; Lirui Wang; Declan F McCole; Katharina Brandl; Peter Stärkel; Clara Belzer; Claus Hellerbrand; Hidekazu Tsukamoto; Samuel B Ho; Bernd Schnabl
Journal:  Hepatology       Date:  2013-05-27       Impact factor: 17.425

6.  Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease.

Authors:  I Bjarnason; C O'Morain; A J Levi; T J Peters
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

7.  Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.

Authors:  Agustín Albillos; Antonio de la Hera; Mónica González; Jose-Luis Moya; Jose-Luis Calleja; Jorge Monserrat; Luis Ruiz-del-Arbol; Melchor Alvarez-Mon
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

8.  What is broad-range 16S rDNA PCR?

Authors:  Amani Patel; Kathryn A Harris; Felicity Fitzgerald
Journal:  Arch Dis Child Educ Pract Ed       Date:  2017-04-17       Impact factor: 1.309

9.  PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial.

Authors:  Charlotte Alexandra Woodhouse; Vishal C Patel; Simon Goldenberg; Alberto Sanchez-Fueyo; Louise China; Alastair O'Brien; Clare Flach; Abdel Douiri; Debbie Shawcross
Journal:  BMJ Open       Date:  2019-02-15       Impact factor: 2.692

10.  Human zonulin, a potential modulator of intestinal tight junctions.

Authors:  W Wang; S Uzzau; S E Goldblum; A Fasano
Journal:  J Cell Sci       Date:  2000-12       Impact factor: 5.285

View more
  5 in total

1.  Probiotics attenuate alcohol-induced muscle mechanical hyperalgesia: Preliminary observations.

Authors:  Paul G Green; Pedro Alvarez; Jon D Levine
Journal:  Mol Pain       Date:  2022 Jan-Dec       Impact factor: 3.395

2.  Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure.

Authors:  Kessarin Thanapirom; Tongluk Teerasarntipan; Sombat Treeprasertsuk; Ashok Choudhury; Manoj K Sahu; Rakhi Maiwall; Viniyendra Pamecha; Richard Moreau; Mamun Al Mahtab; Yogesh Kumar Chawla; Harshad Devarbhavi; Chen Yu; Qin Ning; Deepak Amarapurkar; Chundamannil E Eapen; Saeed Sadiq Hamid; Amna Subhan Butt; Dong Joon Kim; Guan H Lee; Ajit Sood; Laurentious A Lesmana; Zaigham Abbas; Gamal Shiha; Diana A Payawal; Man-Fung Yuen; Albert Chan; George Lau; Jidong Jia; Salimur Rahman; Barjesh C Sharma; Osamu Yokosuka; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-11-25       Impact factor: 6.047

Review 3.  How Advanced Is Our Understanding of the Role of Intestinal Barrier Dysfunction in the Pathogenesis of Recurrent Urinary Tract Infections.

Authors:  Natalia Stepanova
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

4.  Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis.

Authors:  Uta S Koepf; Sebastian Scheidt; Gunnar T R Hischebeth; Christian P Strassburg; Dieter C Wirtz; Thomas M Randau; Philipp Lutz
Journal:  BMC Infect Dis       Date:  2022-04-19       Impact factor: 3.667

5.  Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients.

Authors:  Zhonghan Sun; Zhi-Gang Song; Chenglin Liu; Shishang Tan; Shuchun Lin; Jiajun Zhu; Fa-Hui Dai; Jian Gao; Jia-Lei She; Zhendong Mei; Tao Lou; Jiao-Jiao Zheng; Yi Liu; Jiang He; Yuanting Zheng; Chen Ding; Feng Qian; Yan Zheng; Yan-Mei Chen
Journal:  BMC Med       Date:  2022-01-20       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.